- PLN55.75m
- PLN51.34m
- PLN10.15m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 37.28 | ||
Price to Tang. Book | 38.35 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 4.79 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -8.8% | ||
Return on Equity | -44.45% | ||
Operating Margin | -8.42% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | PLNm | 4.1 | 6.07 | 6.45 | 7.24 | 10.15 | n/a | n/a | 16% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | -89.16 | +463.55 | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Read-Gene SA is a Poland-based company active in the biotechnology sector. It is focused on technologies which aim is to detect, prevent and treat malignant tumors. The Company specializes in three fields: chemoprevention, clinical trials and genetic testing. It offers breast cancer, colon cancer and prostate cancer tests, as well as, medical consultancy, DNA tests and supplements. The Company operates one wholly owned subsidiary, Dieta Antyrakowa Read-Gene Sp. z o.o. Its major shareholder is GEN-PAT-MED Sp. z o.o.
Directors
- Bronislaw Ziemianin CSU
- Jan Lubinski CMG (65)
- Tomasz Huzarski VSU
- Cezary Cybulski OTH (63)
- Karolina Ertmanska OTH
- Adam Gliszczynski SUB
- Jacek Gronwald SUB
- Janusz Pirog SUB
- Adam Szuba SUB
- Dariusz Wiecaszek SUB
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- September 27th, 2005
- Public Since
- February 12th, 2009
- No. of Employees
- 11
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Warsaw Stock Exchange
- Shares in Issue
- 9,449,731
- Address
- Ul. Akacjowa 2, SZCZECIN, 71-253
- Web
- https://read-gene.com/
- Phone
- +48 914334256
- Contact
- Monika Ewert-Krzemieniewska
- Auditors
- Firma Audytorsko – Konsultingowa „PER SALDO" Spólka z o.o
Upcoming Events for RDG
Similar to RDG
Bioton SA
Warsaw Stock Exchange
Braster SA
Warsaw Stock Exchange
Captor Therapeutics SA
Warsaw Stock Exchange
E-Shopping SA
Warsaw Stock Exchange
Genomed SA
Warsaw Stock Exchange
FAQ
As of Today at 23:20 UTC, shares in Read Gene SA are trading at PLN5.90. This share price information is delayed by 15 minutes.
Shares in Read Gene SA last closed at PLN5.90 and the price had moved by +93.29% over the past 365 days. In terms of relative price strength the Read Gene SA share price has outperformed the FTSE Global All Cap Index by +74.33% over the past year.
There is no consensus recommendation for this security.
Find out moreRead Gene SA does not currently pay a dividend.
Read Gene SA does not currently pay a dividend.
Read Gene SA does not currently pay a dividend.
To buy shares in Read Gene SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of PLN5.90, shares in Read Gene SA had a market capitalisation of PLN55.75m.
Here are the trading details for Read Gene SA:
- Country of listing: Poland
- Exchange: WSE
- Ticker Symbol: RDG
Based on an overall assessment of its quality, value and momentum Read Gene SA is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Read Gene SA. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +9.17%.
As of the last closing price of PLN5.90, shares in Read Gene SA were trading +11.41% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Read Gene SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at PLN5.90.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Read Gene SA's management team is headed by:
- Bronislaw Ziemianin - CSU
- Jan Lubinski - CMG
- Tomasz Huzarski - VSU
- Cezary Cybulski - OTH
- Karolina Ertmanska - OTH
- Adam Gliszczynski - SUB
- Jacek Gronwald - SUB
- Janusz Pirog - SUB
- Adam Szuba - SUB
- Dariusz Wiecaszek - SUB